NEW YORK — During a presentation at OSN New York 2019, John A. Hovanesian, MD, FACS, discusses a problematic case study.
Author: Healio ophthalmology
Adverum reports significant progress with intravitreal gene therapy program
Adverum Biotechnologies has made significant progress in its lead clinical program for intravitreal gene therapy for retinal diseases, Leone Patterson, CEO and president, said at the J.P. Morgan Healthcare Conference.Real-world anti-VEGF patient outcom…
Phase 3 trial to investigate Port Delivery System in DME
Genentech and Roche initiated a phase 3 clinical trial to investigate the Port Delivery System with ranibizumab to treat patients with diabetic macular edema, according to a press release.The Port Delivery System (PDS) is a refillable eye implant desig…
VIDEO: Presbyopic IOL challenge
NEW YORK — During a presentation at OSN New York 2019, William F. Wiley, MD, reviews his use of the Kamra inlay (CorneaGen) to address a difficult presbyopia case.
Kala completes enrollment in STRIDE 3 trial
Kala Pharmaceuticals has completed enrollment in the STRIDE 3 trial for KPI-121 0.25%, a treatment for temporary dry eye relief, according to a press release.The enrollment follows a previous new drug application rejection from the FDA, which said that…
Q&A: Vision training to improve athletic performance
Athletes are continually looking for ways to improve their performance and gain an advantage in training to give them a leg up on their competition.Professional and collegiate athletes are embracing vision training and new technologies to heighten thei…
Glaukos leverages acquisitions to enter new ophthalmology spaces
With recent acquisitions, Glaukos now has multiple products in development that expand its reach outside of the glaucoma space and into more comprehensive ophthalmology, CEO Tom Burns said at the J.P. Morgan Healthcare Conference.“Our mission at Glauko…
First US patient implanted with wireless retinal device
A surgeon at the UPMC Eye Center has implanted the first patient in the United States with a wireless retinal device to restore partial sight to those with advanced age-related macular degeneration.The Prima system (Pixium Vision), implanted as part of…
SURGICAL VIDEO: Capsulorrhexis run management when all breaks loose
This surgery showcases the steps involved in a complication management of coloboma cataract. The surgeon, while implanting the IOL, had a rhexis run posteriorly, and the surgeon salvages the situation by changing gears from plan A to plan B and eventua…
Where does your financial advisor’s duty lie?
by Sanjeev Bhatia, MD, and David B. Mandell, JD, MBAIn the first article of this three-part series on investing we discussed the potential pitfalls of going it alone; current evidence suggests that most physician investors will benefit from working wit…
Ocular changes differ in ground-based analogue of weightlessness
Subjects who underwent a ground-based analogue of weightlessness experienced greater peripapillary total retinal thickness but less choroidal thickening compared with astronauts during approximately 30 days of spaceflight, according to a study.“NASA is…
FDA, NIDA call for marijuana legislation to advance public health
Leaders from the FDA and the National Institute on Drug Abuse said during a recent House Committee on Energy and Commerce hearing that there is a pressing need for federal laws that allow more research into marijuana, including research investigating t…
Oyster Point’s dry eye nasal spray meets phase 2 endpoints
Oyster Point Pharma’s nasal spray treatment for dry eye disease has met its primary endpoints in the phase 2 MYSTIC trial, CEO and President Jeffrey Nau, PhD, said at the J.P. Morgan Healthcare Conference.OC-01 (varenicline) nasal spray is a selective …
CustomFlex artificial iris receives transitional pass-through payment status
The CustomFlex artificial iris was granted transitional pass-through payment status from CMS, effective Jan. 1, 2020.The artificial iris from VEO Ophthalmics was approved by the FDA in May 2018 and is the only iris prosthesis available in the United St…
LumiThera completes Series C funding tranche
LumiThera has completed the second tranche of its Series C funding round to support clinical testing and commercialization of the Valeda light delivery system in dry age-related macular degeneration, according to a press release.The funding round was l…
Santen plans entry in US glaucoma market
Santen plans to break into the U.S. glaucoma market in 2020 with the introduction of the DE-128 microshunt, according to a speaker at the 38th annual J.P. Morgan Healthcare Conference.“Glaucoma is one of the leading causes for blindness in many develop…
Iveric plans design of new Zimura trial
Iveric bio announced the design of a second pivotal trial for Zimura, a complement C5 inhibitor in development for the treatment of geographic atrophy.Following the positive results of a phase 2b trial, the company plans to randomly assign 400 patients…
STAAR’s EVO, Visian ICLs receive CE mark as supplemental lens
European authorities have granted a CE mark approval to STAAR Surgical’s ICL as a supplemental or “piggyback” lens in post-cataract IOL surgery, according to a press release.The approval is for the EVO/EVO+ and Visian ICLs for myopia and hyperopia and …
Asymmetric keratoconus correction may improve visual acuity, refractive outcomes
A progressive thickness intrastromal corneal ring segment may help improve visual acuity and refractive outcomes in patients with asymmetric keratoconus, according to a retrospective, observational, single-center clinical study.One hundred four eyes of…
Steroid administration to change in next cohorts of Adverum’s OPTIC trial
Adverum Biotechnologies will change how patients receive steroids to manage inflammation in the third and fourth cohorts of its phase 1 OPTIC trial, the company announced in a press release.The multicenter, open-label, dose-escalation OPTIC trial is as…